Observational studyBMC pulmonary medicine2026
Anti-Ro-52 antibody is a risk factor for recurrence in interstitial lung disease with positive anti-aminoacyl tRNA synthetase antibody: a single-center, retrospective observational study.
Observational study in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-synthetase syndrome-associated interstitial lung disease (ASyS-ILD) frequently recurs, and its recurrence is associated with poor long-term outcomes. Although anti-Ro52 antibodies have been linked to rapidly progressing ILD, their role in ASyS-ILD recurrence remains unclear. This study aimed to investigate the association between anti-Ro52 antibody positivity and ASyS-ILD recurrence.
methodsThis single-center retrospective study included 96 patients with ASyS-ILD who received induction therapy with corticosteroids and immunosuppressants between January 2010 and August 2023. Patients were classified by anti-Ro52 antibody status. The primary analysis was performed using a Fine and Gray competing risks model to assess recurrence or ILD-related death, with non-ILD-related death as a competing event. We performed a multivariable competing risks regression analysis using the Fine-Gray sub-distribution hazards model to evaluate the effect of variables on the cumulative incidence of the main outcome.
resultsForty-four patients were anti-Ro52 positive, and 52 were negative. There were no significant differences in initial treatment regimens. The anti-Ro52 group had a significantly higher incidence of recurrence or ILD-related death in the Fine and Gray model (HR: 2.11, 95% CI: 1.21-3.69, P = 0.008). Multivariable competing risks regression analysis also identified anti-Ro52 positivity as a risk factor for recurrence (HR: 1.77, 95% CI: 1.00-3.11, P = 0.049).
conclusionsAnti-Ro52 antibody positivity is associated with increased risk of recurrence in ASyS-ILD. These findings suggest that anti-Ro52 status may serve as a useful biomarker to identify patients who require close monitoring and long-term management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.